Search Result

Results for "

item/HY-13631

" in MedChemExpress (MCE) Product Catalog:

標的別:	ADC Antibody (1) ADC Linker (2) ADC Payload (47) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (4) Apoptosis (5) Cannabinoid Receptor (1) CD2 (1) Drug Derivative (9) Drug Intermediate (10) Drug-Linker Conjugates for ADC (73) EGFR (1) Endogenous Metabolite (4) Estrogen Receptor/ERR (1) Isotope-Labeled Compounds (9) Leukotriene Receptor (1) Microtubule/Tubulin (13) mTOR (1) Prostaglandin Receptor (1) Reference Standards (2) Small Interfering RNA (siRNA) (1) TGF-beta/Smad (1) Topoisomerase (93) Transmembrane Glycoprotein (1)
研究分野別:	Cancer (127) Cardiovascular Disease (1) Endocrinology (1) Infection (2) Metabolic Disease (5)
クリックケミストリー:	DBCO (1) Alkynes (1)
Oligonucleotides:	Human Pre-designed siRNA Sets (1) siRNAs (1)

150

阻害剤およびアゴニスト

スクリーニングライブラリ

蛍光色素

生化学アッセイ試薬

阻害性抗体

天然物

同位体標識化合物

クリックケミストリー

オリゴヌクレオチド

Targets Recommended: HyT

製品番号	製品名	Target	研究分野	構造式

HY-13631E

Deruxtecan Maximum Cited Publications 25 Publications Verification MC-GGFG-DXD	Drug-Linker Conjugates for ADC	Cancer
Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .

HY-13631D

DXd 10+ Cited Publications Exatecan derivative for ADC	Topoisomerase ADC Payload	Cancer
DXd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC₅₀ of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).

HY-13631

Exatecan 20+ Cited Publications DX-8951	ADC Payload Topoisomerase	Cancer
Exatecan (DX-8951) is a DNA topoisomerase I inhibitor, with an IC₅₀ of 2.2 μM (0.975 μg/mL), and can be used in cancer research.

HY-13631A

Exatecan mesylate 20+ Cited Publications DX8951f	ADC Payload Topoisomerase	Cancer
Exatecan mesylate (DX8951f) is a DNA topoisomerase I inhibitor, with an IC₅₀ of 2.2 μM (0.975 μg/mL). Exatecan mesylate can be used in cancer research.

HY-13631AS

Exatecan-d5 mesylate DX8951f-d5; Deuterated labeled Exatecan mesylate	Isotope-Labeled Compounds ADC Payload Topoisomerase	Cancer
Exatecan-d₅ (DX8951f-d₅) mesylate is deuterium labeled Exatecan mesylate (HY-13631A). Exatecan mesylate is a DNA topoisomerase I inhibitor, with an IC₅₀ of 2.2 μM (0.975 μg/mL). Exatecan mesylate can be used in cancer research .

HY-42487

Exatecan Intermediate 1	ADC Payload Topoisomerase	Cancer
Exatecan Intermediate 1 (compound 6) is an intermediate of Exatecan (HY-13631). Exatecan is a DNA topoisomerase I inhibitor with anticancer effects .

HY-145929

MC-Val-Cit-PAB-Exatecan 1 Publications Verification MC-Val-Cit-PAB-DX8951	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951) is a agent-linker conjugate for ADC. MC-Val-Cit-PAB-Exatecan is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker.

HY-148668

MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan SHR-A1811 Drug-linker	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan (SHR-A1811 Drug-linker) is a agent-linker conjugates for ADC, consisting Exatecan (HY-13631). Exatecan is a DNA Topoisomerase I inhibitor (IC₅₀=2.2 μM) .

HY-13631R

Exatecan (Standard) DX-8951 (Standard)	ADC Payload Reference Standards Topoisomerase	Cancer
Exatecan (Standard) is the analytical standard of Exatecan. This product is intended for research and analytical applications. Exatecan (DX-8951) is a DNA topoisomerase I inhibitor, with an IC₅₀ of 2.2 μM (0.975 μg/mL), and can be used in cancer research.

HY-13631DS

DXd-d5 Exatecan-d₅ derivative for ADC	Topoisomerase ADC Payload	Cancer
DXd-d₅ is a deuterium labeled DXd. DXd is a potent DNA topoisomerase I inhibitor, with an IC₅₀ of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) .

HY-147270

MC-VA-PAB-Exatecan 1 Publications Verification	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-VA-PAB-Exatecan is a agent-linker conjugate for ADC. MC-VA-PAB-Exatecan contains the ADC linker (peptide MC-VA-PAB) and a DNA topoisomerase I inhibitor Exatecan (HY-13631). MC-VA-PAB-Exatecan synthesized ADC shows good antitumor activity .

HY-13631AG

Exatecan mesylate DX8951f	ADC Payload Topoisomerase	Cancer
Exatecan mesylate (DX8951f ) GMP is a GMP-class Exatecan (HY-13631). Exatecan is a DNA topoisomerase I inhibitor, with an IC₅₀ of 2.2 μM (0.975 μg/mL), and can be used in cancer research .

HY-153031

Val-Cit-PAB-Exatecan Val-Cit-PAB-DX8951	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Val-Cit-PAB-Exatecan (Val-Cit-PAB-DX8951) is a agent-linker conjugate for ADC. Val-Cit-PAB-Exatecan is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker .

HY-13631M

Gly-Gly-Phe-Gly-NH-O-CO-Exatecan	Drug-Linker Conjugates for ADC	Cancer
Gly-Gly-Phe-Gly-NH-O-CO-Exatecan is a Drug-Linker Conjugates for ADC, consiting of an ADC linker and Exatecan (HY-13631) (topoisomerase I inhibitor). Gly-Gly-Phe-Gly-NH-O-CO-Exatecan can be used for ADC molecues synthesis.

HY-13631EG

Deruxtecan MC-GGFG-DXD	Drug-Linker Conjugates for ADC	Cancer
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .

HY-13631J

(1R,9R)-Exatecan mesylate (1R,9R)-DX8951f	Drug Derivative Topoisomerase Apoptosis	Cancer
(1R,9R)-Exatecan mesylate ((1R,9R)-DX8951f) is a non-prodrug camptothecin derivative and a potent topoisomerase I inhibitor (IC₅₀=0.975 μg/mL in mice and 0.82 μg/mL in humans). (1R,9R)-Exatecan mesylate blocks enzyme activity and induces apoptosis by stabilizing the enzyme-DNA cleavable complex. (1R,9R)-Exatecan mesylate not only effectively inhibits the proliferation of various malignant tumor cells and tumor growth, but also circumvents P-glycoprotein-mediated multidrug resistance. (1R,9R)-Exatecan mesylate is widely used in preclinical studies of multiple cancers including pancreatic cancer, lung cancer, breast cancer, and leukemia . The low-activity isomer of (1R,9R)-Exatecan mesylate is (1S,9R)-Exatecan mesylate (HY-13631I).

HY-164835

VcMMAE-Deruxtecan SMP-54418	Drug-Linker Conjugates for ADC Microtubule/Tubulin Topoisomerase	Cancer
VcMMAE-Deruxtecan (SMP-54418) is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule MMAE (HY-15162) (Microtubule inhibitor) and Exatecan (HY-13631) (DNA topoisomerase I inhibitor). VcMMAE-Deruxtecan can be used for ADC synthesis.

HY-147095

Val-Ala-PABC-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Val-Ala-PABC-Exatecan is a Drug-Linker Conjugates for ADC, consiting of a cleavable Tesirine linker (Val-Ala-PABC) and Exatecan (HY-13631) (topoisomerase I inhibitor). Val-Ala-PABC-Exatecan can be used for ADC molecues synthesis, such as Mal-PEGn-amide-va-Exatecan .

HY-44369

Exatecan Intermediate 6	ADC Payload Topoisomerase	Cancer
Exatecan Intermediate 6 is the intermediate of Exatecan (HY-13631) And Exatecan (DX-8951) is a DNA topoisomerase I inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL) that can be used in cancer research. Exatecan Intermediate 6 can be used to synthesize Antibody-Drug Conjugates (ADCs).

HY-164792

DBCO-PEG3-VC-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
DBCO-PEG3-VC-Exatecan (compound 25) is a Drug-Linker Conjugate for ADC. DBCO-PEG3-VC-Exatecan contains the ADC linker (DBCO-PEG3-VC) and a DNA topoisomerase I inhibitor Exatecan (HY-13631) .

HY-171580

Mc-PEG4-Val-Ala-PAB-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Mc-PEG4-Val-Ala-PAB-Exatecan is a Drug-linker conjugate for ADC. Mc-PEG4-Val-Ala-PAB-Exatecan contains the ADC linker (Mc-PEG4-Val-Ala-PAB) and a DNA topoisomerase I inhibitor Exatecan (HY-13631) .

HY-W021377

Exatecan Intermediate 2	ADC Payload Drug Intermediate	Cancer
Exatecan Intermediate 2 (Compound B) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .

HY-153069

GGFG-PAB-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
GGFG-PAB-Exatecan consists of an ADC toxin Exatecan (HY-13631) and a linker GGFG-PAB, and can be used as a drug-linker conjugate for the synthesis of ADC molecules .

HY-13631F

Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Gly-Gly-Phe-Gly-NH-O-CO-Exatecan, as a drug-linker conjugate composed of linker Gly-Gly-Phe-Gly-NH-O-CO and Exatecan, can be used to prepare antibody conjugate drugs. Exatecan is a DNA topoisomerase I inhibitor that can be used in cancer research .

HY-13631I

(1S,9R)-Exatecan mesylate (1S,9R)-DX8951f	Drug Derivative Topoisomerase Apoptosis	Cancer
(1S,9R)-Exatecan mesylate ((1S,9R)-DX8951f) is a non-prodrug camptothecin derivative and a topoisomerase I inhibitor (IC₅₀=0.975 μg/mL in mice and 0.82 μg/mL in humans). (1S,9R)-Exatecan mesylate blocks enzyme activity and induces apoptosis by stabilizing the enzyme-DNA cleavable complex. (1S,9R)-Exatecan mesylate not only effectively inhibits the proliferation of various malignant tumor cells and tumor growth, but also circumvents P-glycoprotein-mediated multidrug resistance. (1S,9R)-Exatecan mesylate is widely used in preclinical studies of various cancers such as pancreatic cancer, lung cancer, breast cancer, and leukemia . The chiral isomer of (1S,9R)-Exatecan mesylate is (1R,9R)-Exatecan mesylate (HY-13631J).

HY-79490

Ac-Exatecan	ADC Payload Topoisomerase	Cancer
Ac-Exatecan is acetylation-modified Exatecan (HY-13631). Exatecan is a common toxin component in ADC preparation (ADC cytotoxin) and an inhibitor of DNA topoisomerase I (IC₅₀ = 2.2 μM). Exatecan has antitumor activity. Exatecan can be used as a payload for ADC. Exatecan is effective against P-glycoprotein mediated multi-drug resistant cells .

HY-156617

Cyclopropaneacetamide-Exatecan	ADC Payload Topoisomerase	Cancer
Cyclopropaneacetamide-Exatecan is an Exatecan (HY-13631) analogue and an ADC Cytotoxin. Cyclopropaneacetamide-Exatecan can be used to synthesize ADC molecules for cancer research .

HY-49412

Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CO-CH3	Drug Intermediate	Others
Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CO-CH3 (compound DC-13-C) is an intermediate in the synthesis of Exatecan (HY-13631) derivatives .

HY-43565

Exatecan intermediate 9	ADC Payload Topoisomerase	Cancer
Exatecan intermediate 9 is an intermediate for the synthesis of Exatecan (HY-13631). Exatecan (DX-8951) is a common toxin component in ADC preparation (ADC Cytotoxin) and an inhibitor of DNA topoisomerase I (IC50=2.2 μM) .

HY-174279

MCC-AAQ-Exa	Drug-Linker Conjugates for ADC	Cancer
MCC-AAQ-Exa is a drug-linker conjugates for ADC, obtained by condensing the linker with Exatecan (HY-13631) and can be used to prepare antibody-drug conjugates (ADCs). MCC is an ADC linker containing a maleimide fragment .

HY-148668A

MC-Gly-Gly-Phe-Gly-(S)-Cyclopropane-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan is a agent-linker conjugates for ADC, consisting Exatecan (HY-13631). Exatecan is a DNA Topoisomerase I inhibitor (IC₅₀=2.2 μM) .

HY-128995A

Glycyl-Exatecan TFA Glycyl-DX-8951 TFA; Exatecan analog 2 TFA	Drug Derivative	Cancer
Glycyl-Exatecan TFA (Glycyl-DX-8951 TFA), a derivative of Exatecan (HY-13631), is an anticancer agent. Glycyl-Exatecan TFA has significantly antitumor activity. Glycyl-Exatecan TFA can be used for cancers like solid tumors research .

HY-168489

OBI-992 drug-linker	Drug-Linker Conjugates for ADC	Cancer
OBI-992 drug-linker is a drug-linker conjugate composed of a TOP I inhibitor Exatecan (HY-13631) and a linker. OBI-992 drug-linker exhibits antitumor property in mouse models and can be used for synthesis of ADC OBI-992 .

HY-177546

DBCO-PEG3-GGFG-Exatecan	Drug-Linker Conjugates for ADC Drug Derivative Topoisomerase	Cancer
DBCO-PEG3-GGFG-Exatecan is a Drug-linker conjugate for ADC. DBCO-PEG3-GGFG-Exatecan contains the ADC linker (DBCO-PEG3-GGFG) and a DNA topoisomerase I inhibitor Exatecan (HY-13631) .

HY-153600

GGFG-amide-glycol-amide-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
GGFG-amide-glycol-amide-Exatecan (Intermediate 2) is an Exatecan (HY-13631) derivative and can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-171931A

Aminocaproyl-Val-Cit-PABC-Exatecan TFA	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Aminocaproyl-Val-Cit-PABC-Exatecan TFA is a drug-linker conjugate for ADC, consiting of a cleavable linker (Aminocaproyl-Val-Cit-PABC) and Exatecan (HY-13631) (topoisomerase I inhibitor). Aminocaproyl-Val-Cit-PABC-Exatecan TFA can be used for ADC molecues synthesis .

HY-177495

LD-38	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
LD-38 is a drug-linker conjugate for ADC. LD-38 consists of a topoisomerase 1 inhibitor (Exatecan) (HY-13631) and a highly hydrophilic stable and cleavable linker. LD-38 can be used for synthesis of ADCs, such as KA-3123-LD38 .

HY-147307

MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan is a agent-linker conjugate for ADC, contains the ADC linker (MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic acid) and a DNA topoisomerase I inhibitor Exatecan (HY-13631). MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan synthesized ADC can be used in study of cancer .

HY-159783

Mal-Exatecan	ADC Payload Topoisomerase	Cancer
Mal-Exatecan is a Mal (Maleimide) modified Exatecan (HY-13631), a DNA topoisomerase I (topoisomerase I) inhibitor .

HY-176976

Exatecan-mpGNNG	Drug-Linker Conjugates for ADC	Cancer
Exatecan-mpGNNG (Compound 10a) is the linker-payload component of an antibody-drug conjugate (ADC). Exatecan-mpGNNG is composed of Exatecan (HY-13631), a potent topoisomerase I inhibitor, and the linker .

HY-13631O

(1R)-Deruxtecan	Drug-Linker Conjugates for ADC	Cancer
(1R)-Deruxtecan is a drug-linker conjugates for ADC .

HY-171931

Aminocaproyl-Val-Cit-PABC-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Aminocaproyl-Val-Cit-PABC-Exatecan is a drug-linker conjugate for ADC, consiting of a cleavable linker (Aminocaproyl-Val-Cit-PABC) and Exatecan (HY-13631) (topoisomerase I inhibitor). Aminocaproyl-Val-Cit-PABC-Exatecan can be used for ADC molecues synthesis .

HY-153031A

Val-Cit-PAB-Exatecan TFA Val-Cit-PAB-DX8951 TFA	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Val-Cit-PAB-Exatecan (Val-Cit-PAB-DX8951) TFA is a agent-linker conjugate for ADC. Val-Cit-PAB-Exatecan TFA is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker .

HY-128994A

GGFG-Exatecan TFA	Drug Intermediate	Cancer
GGFG-Exatecan TFA is a synthetic intermediate for drug-linker conjugates used in antibody-drug conjugates (ADCs). GGFG-Exatecan TFA consists of a glycyl-glycyl-phenylalanyl-glycine (GGFG) tetrapeptide linker and a DNA topoisomerase I inhibitor Exatecan (HY-13631). GGFG-Exatecan TFA can be used for the study of cancer .

HY-W021377B

Exatecan Intermediate 4	ADC Payload Drug Intermediate	Cancer
Exatecan Intermediate 4 (Compound 14f) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .

HY-160806

(5-Cl)-Exatecan	ADC Payload Topoisomerase	Cancer
(5-Cl)-Exatecan is a derivative of Exatecan (HY-13631) and a DNA topoisomerase inhibitor. (5-Cl)-Exatecan serves as the cytotoxic payload component in antibody-drug conjugates (ADC) targeting ROR1-positive cancers. (5-Cl)-Exatecan is applicable for the research of ROR1-positive cancers .

HY-148696A

Gly-Cyclopropane-Exatecan	ADC Payload Topoisomerase	Cancer
Gly-Cyclopropane-Exatecan involves in the synthesis of anti-B7-H4 ADC, containing Exatecan (HY-13631), a DNA Topoisomerase I inhibitor. Gly-Cyclopropane-Exatecan participated in the formation of the ADC hu2F7-Exatecan (compound 34), which showed antitumor activity in vivo and in vitro .

HY-160755

UM-2	Endogenous Metabolite	Others
UM-2 is the urinary 3-hydroxy metabolite of DX-8951 (HY-13631) in human .

HY-153185

Decyclohexanamine-Exatecan	ADC Payload Topoisomerase	Cancer
Decyclohexanamine-Exatecan (compound a) is a Camptothecin derivative, with a structure containing Exatecan (HY-13631), which can be used as a ADC cytotoxin .

HY-168317

LNK2-S	Drug-Linker Conjugates for ADC	Cancer
LNK2-S is a conjugated compound of toxin molecule Exatecan (HY-13631) and Linker, which can be used to synthesize ADC molecule .

製品番号	製品名

HY-L0096V

Vitas-M Screening Compounds Library	1,400,000 compounds
Vitas-M Screening Compounds Library (stock) contains about 1,400,000 chemical substances. They are synthetic small molecule organic compounds for biological screening and lead optimization. Select any number of items as a "cherry pick".

HY-L055

Medicine Food Homology Compound Library

1,801 compounds

Medicine Food Homology (MFH) means that some food themselves are medicines and there is no absolute boundary between them. MFH theory combines the function of food and medicine together scientifically and MFH materials can be used both for food and medicine. Besides nutritional value, MFH materials also have the functions in the prevention and treatment of disease and many other healthcare effects. Food as medicines has many benefits because of their safety while taking drugs will bring inevitable side effect to people. In order to ensure the safe use of functional food, National Health Commission of People's Republic of China made specific provisions on MFH items. More than 100 kinds of widely used MFH materials have been released.

Based on MFH items released by National Health Commission, PRC, MCE carefully designs a unique collection of 1,801 Medicine Food Homology Compounds with high safety that can be used for high throughput and high content screening for drug discovery.

HY-L0088V

Life Chemicals 50K Diversity Library

50,240 compounds

Life Chemicals presents a number of exclusive Pre-Plated Diversity Sets composed of 50,240 novel compounds with optimal physicochemical properties selected from Life Chemicals collection of newly synthesized items by dissimilarity search with an average Tanimoto threshold of 82%. These Diverse Screening Sets are ideal starting points for customers looking for a wide range of dissimilarity to screen against a number of targets from different classes or where little information is available on targeted protein structure.

製品番号	製品名	Type

HY-177434

Precemtabart tocentecan

Precem-TcT; M 9140

蛍光色素

Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC .

HY-13631AG

Exatecan mesylate DX8951f	蛍光色素
Exatecan mesylate (DX8951f ) GMP is a GMP-class Exatecan (HY-13631). Exatecan is a DNA topoisomerase I inhibitor, with an IC₅₀ of 2.2 μM (0.975 μg/mL), and can be used in cancer research .

HY-13631EG

Deruxtecan MC-GGFG-DXD	蛍光色素
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .

HY-173639

AZD0516

蛍光色素

AZD0516 is a first-in-class antibody-drug conjugate (ADC) targeting six-transmembrane epithelial antigen of the prostate-2 (STEAP2). The anti-STEAP2 monoclonal antibody (mAb) is conjugated via interchain cysteines to a maleimide-reactive, β-glucuronidase-cleavable linker (HY-173635) bearing the topoisomerase 1 inhibitor, Exatecan (HY-13631). AZD0516 can be used for the study of prostate cancer .

HY-158109

M3554	蛍光色素
M3554 is an anti-GD2 antibody-drug conjugate (ADC) based on the humanized anti-GD2 antibody. M3554 consists of the humanized monoclonal antibody hu14.18 (K322A) (HY-P991040) linked to a topoisomerase 1 inhibitor Exatecan (HY-13631) via a cleavable β-glucuronide linker. M3554 can be used for the study of neuroblastoma, osteosarcoma or glioma .

HY-171747

AMT-562	蛍光色素
AMT-562 is an antibody-drug conjugate (ADC) consisting of a novel anti-HER3 antibody Ab562 (HY-P991505) conjugated to the linker MC-VA-PAB and the topoisomerase I inhibitor Exatecan (HY-13631). The ADC toxic molecule and linker portion are MC-VA-PAB-Exatecan (HY-147270). AMT-562 can induce apoptosis and has antitumor activity against pancreatic, esophageal, and gastric cancers .

製品番号	製品名	Type

HY-13631AG

Exatecan mesylate DX8951f	生化学アッセイ試薬
Exatecan mesylate (DX8951f ) GMP is a GMP-class Exatecan (HY-13631). Exatecan is a DNA topoisomerase I inhibitor, with an IC₅₀ of 2.2 μM (0.975 μg/mL), and can be used in cancer research .

HY-13631EG

Deruxtecan MC-GGFG-DXD	生化学アッセイ試薬
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .

製品番号	製品名	Target	研究分野	Image

HY-P991742

LY4101174 Antibody 15A7.5; ETx-22 Antibody	ADC Antibody	Cancer
LY4101174 Antibody is an ADC antibody. LY4101174 is an antibody-drug conjugate (ADC) that targets the nectin-4 protein present on the surface of certain cancer cells. It can directly deliver a potent chemotherapy agent (Exatecan (HY-13631)) to the tumor site and is used for the study of advanced cancers, such as urothelial carcinoma, triple-negative breast cancer, and non-small cell lung cancer .

HY-P992356

GENA-104A16	Topoisomerase	Cancer
GENA-104A16 is a humanized monoclonal antibody targeting CNTN4, with multiple functions including immunostimulation, cytotoxicity and immunoregulation. By binding to CNTN4, GENA-104A16 blocks its interaction with APP, thereby restoring T cell function, inducing tumor cell death and regulating tumor-infiltrating immune cell populations. GENA-104A16 also exerts topoisomerase I inhibitory activity via the payload Exatecan (HY-13631). GENA-104A16 can be used in research related to colon cancer liver metastasis and other CNTN4-expressing solid tumors .

製品番号	製品名	Category	Target	構造式

HY-N13631

5-O-Methyllatifolin	Dalbergia cochinchinensis Monophenols Papilionaceae Phenols Plants Source Classification	Others
5-O-Methyllatifolin is a natural product .

製品番号	製品名	構造式

HY-13631AS

Exatecan-d5 mesylate
Exatecan-d₅ (DX8951f-d₅) mesylate is deuterium labeled Exatecan mesylate (HY-13631A). Exatecan mesylate is a DNA topoisomerase I inhibitor, with an IC₅₀ of 2.2 μM (0.975 μg/mL). Exatecan mesylate can be used in cancer research .

HY-13631DS

DXd-d5
DXd-d₅ is a deuterium labeled DXd. DXd is a potent DNA topoisomerase I inhibitor, with an IC₅₀ of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) .

HY-128995AS

Glycyl-Exatecan-d5 hydrochloride
Glycyl-Exatecan-d₅ (Glycyl-DX-8951-d₅) hydrochloride is deuterium labeled Glycyl-Exatecan (HY-128995A). Glycyl-Exatecan (Glycyl-DX-8951), a derivative of Exatecan (HY-13631), is an anticancer agent. Glycyl-Exatecan has significantly antitumor activity. Glycyl-Exatecan can be used for cancers like solid tumors research.

HY-13631ES4

Deruxtecan-d5
Deruxtecan-d₅ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-13631ES3

Deruxtecan-d2
Deruxtecan-d₂ is the deuterium labeled Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-13631ES

Deruxtecan-d4
Deruxtecan-d₄ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-13631ES2

Deruxtecan-d4-1
Deruxtecan-d₄-1 is the deuterium labeled Adenosine Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-13631ES1

Deruxtecan-d6
Deruxtecan-d₆ is the deuterium labeled Deruxtecan .

HY-13631AS1

Exatecan-d3 mesylate
Exatecan-d₃ (DX8951f-d₃) mesylate is deuterium-labeled Exatecan mesylate (HY-13631A). Exatecan mesylate is a DNA topoisomerase I inhibitor, with an IC₅₀ of 0.975 μg/mL .

HY-45171S

Exatecan intermediate 12-d5
Exatecan intermediate 12-d₅ is the deuterium labeled Exatecan intermediate 12 (HY-45171). Exatecan intermediate 12 is an intermediate for the synthesis of ADC toxin Exatecan (HY-13631) and can be used to prepare ADC compounds.

HY-42487S1

Exatecan Intermediate 1-d2
Exatecan Intermediate 1-d₂ is the deuterium labeled Exatecan Intermediate 1 (HY-42487). Exatecan Intermediate 1 (compound 6) is an intermediate of Exatecan (HY-13631). Exatecan is a DNA topoisomerase I inhibitor with anticancer effects.

製品番号	製品名		Classification

HY-164792

DBCO-PEG3-VC-Exatecan		DBCO
DBCO-PEG3-VC-Exatecan (compound 25) is a Drug-Linker Conjugate for ADC. DBCO-PEG3-VC-Exatecan contains the ADC linker (DBCO-PEG3-VC) and a DNA topoisomerase I inhibitor Exatecan (HY-13631) .

HY-173625

P5(PEG12)-VC-PAB-Exatecan		Alkynes
P5(PEG12)-VC-PAB-Exatecan (LP3) is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor Exatecan (HY-13631) and a linker P5(PEG24)-VC-PAB to make antibody agent conjugate (ADC). P5(PEG12)-VC-PAB-Exatecan can be used for the research of tumor .

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: